Combination therapy with lamivudine and famciclovir for chronic hepatitis B infection Hong Shen, Mazen Alsatie, George Eckert, Naga Chalasani, Lawrence.

Slides:

Advertisements

Similar presentations

Entecavir Superior to Lamivudine for Treatment of Nucleoside-Naive, HBeAg- Negative Patients Slideset on: Lai CL, Shouval D, Lok AS, et al. Entecavir versus.

Advertisements

Adefovir Suppresses HBV DNA Levels in Lamivudine-Resistant HIV/HBV Patients Slideset on: Benhamou Y, Thibault V, Vig P, et al. Safety and efficacy of adefovir.

Clinical Factors Associated With Liver Stiffness in Hepatitis B e Antigen–Positive Chronic Hepatitis B Patients Grace Lai–Hung Wong, Vincent Wai–Sun.

Volume 67, Issue 2, Pages (August 2017)

Volume 39, Issue 6, Pages (December 2003)

Incorrect Calculation and Inappropriate Interpretation: Accuracy of International Guidelines for Identifying Significant Fibrosis in e Antigen–Negative.

Chronic Hepatitis C Therapy: Changing the Rules of Duration

Volume 136, Issue 4, Pages (April 2009)

Halis Simsek, Ali Shorbagi, Yasemin Balaban, Gonca Tatar

Volume 136, Issue 4, Pages (April 2009)

Volume 140, Issue 2, Pages e1 (February 2011)

Volume 139, Issue 6, Pages (December 2010)

A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: 2008 Update Emmet B. Keeffe, Douglas T. Dieterich,

Uchenna H. Iloeje, Hwai–I

Effectiveness of Hepatitis B Treatment in Clinical Practice

Level of Hepatitis B Virus DNA in Inactive Carriers With Persistently Normal Levels of Alanine Aminotransferase Chia–Ming Chu, Yi–Cheng Chen, Dar–In.

Volume 127, Issue 6, Pages (December 2004)

Suna Yapali, Nizar Talaat, Anna S. Lok

Management of Dyslipidemia as a Cardiovascular Risk Factor in Individuals With Nonalcoholic Fatty Liver Disease Kathleen E. Corey, Naga Chalasani Clinical.

Clinical Factors Associated With Liver Stiffness in Hepatitis B e Antigen–Positive Chronic Hepatitis B Patients Grace Lai–Hung Wong, Vincent Wai–Sun.

Volume 50, Issue 4, Pages (April 2009)

Volume 133, Issue 5, Pages (November 2007)

Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C Chi–Jen Chu, Munira Hussain,

GI clinical research 2002–2003: the year in review

Volume 154, Issue 4, Pages (March 2018)

Volume 130, Issue 7, Pages (June 2006)

Volume 130, Issue 4, Pages (April 2006)

Fulminant hepatic failure as the initial presentation of acute autoimmune hepatitis William R Kessler, Oscar W Cummings, George Eckert, Naga Chalasani,

Virologic Response to Therapy Increases Health-Related Quality of Life for Patients With Chronic Hepatitis B Jeong Han Kim, So Young Kwon, Young Sok.

Dhanashri Kolwankar, Raj Vuppalanchi, Brian Ethell, David R

Early Virologic Responses and Hematologic Safety of Direct-Acting Antiviral Therapies in Veterans With Chronic Hepatitis C Pamela S. Belperio, Elizabeth.

Nghia H. Nguyen, Vincent Nguyen, Huy N. Trinh, Brian Lin, Mindie H

Interpreting Hepatitis B Surface Antigen Levels: Useful Clinical Test or Just Another Confusing Assay? Brian J. McMahon, MD, Brenna C. Simons, PhD Clinical.

Chronic Hepatitis B: Current Testing Strategies

Incidence of Statin Hepatotoxicity in Patients With Hepatitis C

Anouk Dev, Keyur Patel, Andrew Conrad, Lawrence M. Blatt, John G

Effectiveness of interferon α-2b and ribavirin combination therapy in the treatment of naive chronic hepatitis C patients in clinical practice1 Thomas.

Severe Constipation Clinical Gastroenterology and Hepatology

Ronnie Fass, Stephen J. Sontag, Barry Traxler, Mark Sostek

Volume 126, Issue 1, Pages (January 2004)

Volume 44, Issue 2, Pages (February 2006)

Chronic Hepatitis B Virus Carriers in the Immunotolerant Phase of Infection: Histologic Findings and Outcome Tony Andreani, Lawrence Serfaty, Djamila.

Scott J. Cotler, Manish K. Dhamija, Fabiolla Siqueira, Anna H

Hepatitis B Immunoglobulin and Lamivudine Improve Hepatitis B–Related Outcomes After Liver Transplantation: Meta-Analysis Rohit Loomba, Ayana K. Rowley,

Volume 132, Issue 7, Pages (June 2007)

Suthat Liangpunsakul, Naga Chalasani, M.D. Kidney International

Volume 139, Issue 2, Pages (August 2010)

Histologic Changes in Liver Tissue From Patients With Chronic Hepatitis B and Minimal Increases in Levels of Alanine Aminotransferase: A Meta-analysis.

Chronic Hepatitis C Therapy: Changing the Rules of Duration

A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: 2008 Update Emmet B. Keeffe, Douglas T. Dieterich,

EASL Clinical Practice Guidelines: Management of chronic hepatitis B

Antiviral therapy for chronic hepatitis B: Challenges in Hong Kong

Sharon J. Hutchinson, Sheila M. Bird, David J. Goldberg

Prevalence and Treatment of Hepatitis C Virus Genotypes 4, 5, and 6

Ten-year follow-up of hepatitis B relapse after cessation of lamivudine or telbivudine treatment in chronic hepatitis B patients H.-Y. Pan, H.-Y. Pan,

Alan Bonder, MD, Nezam H. Afdhal, MD

Suna Yapali, MD, Anna S. Lok, MD, FRCP

Chronic Diarrhea Clinical Gastroenterology and Hepatology

Chronic hepatitis B in children and adolescents

Christos Konstantakis, Maria Karamesini, Christos Triantos

Predictors of Early Treatment Discontinuation Among Patients With Genotype 1 Hepatitis C and Implications for Viral Eradication Lauren A. Beste, George.

Severe irritable bowel and functional abdominal pain syndromes: Managing the patient and health care costs George F. Longstreth, Douglas A. Drossman

A 27-Year-Old Woman With Constipation: Diagnosis and Treatment

Management of Hepatitis B

Clinical Gastroenterology and Hepatology

Volume 137, Issue 6, Pages (December 2009)

Reply Gastroenterology

Scott K. Fung, Anna S.F. Lok Clinical Gastroenterology and Hepatology

Emmet B. Keeffe, Douglas T

Clinical, Radiologic, and Manometric Characteristics of Chronic Intestinal Dysmotility: The Stanford Experience Lucilene Rosa-e-Silva, Lauren B. Gerson,

Presentation transcript:

Combination therapy with lamivudine and famciclovir for chronic hepatitis B infection Hong Shen, Mazen Alsatie, George Eckert, Naga Chalasani, Lawrence Lumeng, Paul Y. Kwo Clinical Gastroenterology and Hepatology Volume 2, Issue 4, Pages 330-336 (April 2004) DOI: 10.1016/S1542-3565(04)00063-1

Figure 1 Distribution of patients in group 1 who received long-term treatment with combination therapy. Despite the development of YMDD mutations by sequencing after an average of 2 years of combination therapy in 3 naive HBeAg subjects, none of them had detectable HBV DNA by Digene assay at 3 years and 3 months of combination therapy (15 months after sample collection for sequencing). Clinical Gastroenterology and Hepatology 2004 2, 330-336DOI: (10.1016/S1542-3565(04)00063-1)

Figure 2 ALT levels are shown for 13 treatment-naive HBeAg-positive subjects during 48 weeks of therapy with lamivudine and famciclovir. A significant improvement in ALT was seen by week 24 that persisted to week 48. Clinical Gastroenterology and Hepatology 2004 2, 330-336DOI: (10.1016/S1542-3565(04)00063-1)